[go: up one dir, main page]

CL2008001374A1 - Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. - Google Patents

Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.

Info

Publication number
CL2008001374A1
CL2008001374A1 CL2008001374A CL2008001374A CL2008001374A1 CL 2008001374 A1 CL2008001374 A1 CL 2008001374A1 CL 2008001374 A CL2008001374 A CL 2008001374A CL 2008001374 A CL2008001374 A CL 2008001374A CL 2008001374 A1 CL2008001374 A1 CL 2008001374A1
Authority
CL
Chile
Prior art keywords
compounds
pde9
schizophrenia
neurodegenerative
alzheimer
Prior art date
Application number
CL2008001374A
Other languages
English (en)
Inventor
Robert Verhoest Patrick
Proulx-Lafrance Caroline
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39672073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CL2008001374A1 publication Critical patent/CL2008001374A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)

Abstract

Compuestos derivados de amino-heterociclos, inhibidores de pde9; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno neurodegenerativo y cognitivo como Alzheimer y esquizofrenia.
CL2008001374A 2007-05-11 2008-05-09 Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. CL2008001374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91733307P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
CL2008001374A1 true CL2008001374A1 (es) 2008-11-14

Family

ID=39672073

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001374A CL2008001374A1 (es) 2007-05-11 2008-05-09 Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.

Country Status (43)

Country Link
US (1) US7964607B2 (es)
EP (1) EP2152712B1 (es)
JP (1) JP4579346B2 (es)
KR (1) KR101222330B1 (es)
CN (1) CN101687876B (es)
AP (1) AP2524A (es)
AR (1) AR066502A1 (es)
AT (1) ATE540954T1 (es)
AU (1) AU2008249750B2 (es)
BR (1) BRPI0811280B8 (es)
CA (1) CA2687035C (es)
CL (1) CL2008001374A1 (es)
CO (1) CO6241157A2 (es)
CR (1) CR11095A (es)
CU (1) CU23834B1 (es)
CY (1) CY1112332T1 (es)
DK (1) DK2152712T3 (es)
DO (1) DOP2009000258A (es)
EA (1) EA016510B1 (es)
EC (1) ECSP099728A (es)
ES (1) ES2377849T3 (es)
GE (1) GEP20125405B (es)
GT (1) GT200900294A (es)
HR (1) HRP20120105T1 (es)
IL (1) IL201977A (es)
MA (1) MA31373B1 (es)
ME (1) ME00954B (es)
MX (1) MX2009011830A (es)
MY (1) MY147330A (es)
NI (1) NI200900204A (es)
NZ (1) NZ580904A (es)
PA (1) PA8779901A1 (es)
PE (1) PE20090247A1 (es)
PL (1) PL2152712T3 (es)
PT (1) PT2152712E (es)
RS (1) RS52166B (es)
SI (1) SI2152712T1 (es)
SV (1) SV2009003411A (es)
TN (1) TN2009000471A1 (es)
TW (1) TWI362262B (es)
UA (1) UA94660C2 (es)
WO (1) WO2008139293A1 (es)
ZA (1) ZA200907776B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
PE20091211A1 (es) 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2736304A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
SI2889033T1 (en) 2008-11-19 2018-08-31 Forum Pharmaceuticals Inc. Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
GEP20146098B (en) 2009-03-31 2014-05-27 Boehringer Ingelheim Int 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
WO2010132423A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2013507360A (ja) * 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
MX344770B (es) 2010-08-12 2017-01-06 Boehringer Ingelheim Int Gmbh * Derivados de 6-cicloalquil-1,5-dihidro-pirazolo (3,4-d) pirimidin-4-onas y su uso como inhibidores de pde9a.
MX2013002584A (es) 2010-09-07 2013-04-29 Astellas Pharma Inc Compuesto de pirazoloquinolina.
WO2012040230A1 (en) 2010-09-20 2012-03-29 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
TWI562993B (en) 2011-10-07 2016-12-21 Eisai R&D Man Co Ltd Pyrazoloquinoline derivatives
CN104703987B (zh) * 2011-10-10 2017-05-03 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
SG11201403909RA (en) * 2012-01-26 2014-10-30 Lundbeck & Co As H Pde9 inhibitors with imidazo triazinone backbone
EP2828262A4 (en) * 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
EP3255049A1 (en) 2012-06-29 2017-12-13 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
PE20151718A1 (es) 2013-04-05 2015-11-22 Eisai Randd Man Co Ltd Compuestos piridinilpirazoloquinolina
MX359843B (es) 2013-04-05 2018-10-12 Eisai R&D Man Co Ltd Sal de derivado de pirazoloquinolina y cristal de la misma.
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
EP3193878B1 (en) * 2014-09-17 2021-01-06 Intra-Cellular Therapies, Inc. 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
HK1243936A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
HK1243935A1 (zh) * 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
WO2016103097A1 (en) 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
CN108348775B (zh) 2015-09-15 2021-07-02 普瑞西斯生物学研究有限责任公司 芬坎法明的前药
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN114903900A (zh) 2016-07-06 2022-08-16 伊马拉公司 用于治疗外周疾病的pde9抑制剂
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
WO2018218104A1 (en) 2017-05-26 2018-11-29 Imara, Inc. Methods of making and using pde9 inhibitors
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
JP7293129B2 (ja) 2017-06-01 2023-06-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｐｄｅ９阻害剤を含む医薬組成物
US11147803B2 (en) 2017-06-01 2021-10-19 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
CN110603040B (zh) 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和多奈哌齐的痴呆治疗剂
KR20200013758A (ko) 2017-06-08 2020-02-07 머크 샤프 앤드 돔 코포레이션 피라졸로피리미딘 pde9 억제제
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Novel uses
CN110357888A (zh) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 杂环磷酸二酯酶抑制剂及其用途
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
US12194042B2 (en) 2018-10-21 2025-01-14 Intra-Cellular Therapies, Inc. Uses
KR102706457B1 (ko) * 2018-12-06 2024-09-11 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CN111471059B (zh) 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
CN118401525A (zh) * 2021-12-16 2024-07-26 辉瑞有限公司 吡唑并[3,4-d]嘧啶化合物的固体形式
EP4444305A2 (en) * 2022-02-16 2024-10-16 Duke Street Bio Limited Pharmaceutical compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
WO2002094790A1 (en) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
JP2005508978A (ja) * 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
WO2004008230A2 (en) * 2002-07-12 2004-01-22 Massachusetts Institute Of Technology Reconfigurable microphotonics devices via deformable membrane platform
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US7051174B2 (en) * 2002-09-24 2006-05-23 International Business Machines Corporation Method, system, and program for restoring data in cache
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
US7111287B2 (en) * 2003-01-10 2006-09-19 International Business Machines Corporation Global processor resource assignment in an assembler
ES2289377T3 (es) 2003-03-18 2008-02-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Nuevas pirazolopirimidonas y su uso como inhibidores de pde.
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine

Also Published As

Publication number Publication date
ECSP099728A (es) 2009-12-28
IL201977A0 (en) 2010-06-16
MA31373B1 (fr) 2010-05-03
AP2009005048A0 (en) 2009-12-31
BRPI0811280B1 (pt) 2021-05-11
CY1112332T1 (el) 2015-12-09
AU2008249750A1 (en) 2008-11-20
CN101687876B (zh) 2012-12-12
AR066502A1 (es) 2009-08-26
EP2152712A1 (en) 2010-02-17
CN101687876A (zh) 2010-03-31
US7964607B2 (en) 2011-06-21
EA016510B1 (ru) 2012-05-30
AP2524A (en) 2012-12-04
CR11095A (es) 2009-12-04
DK2152712T3 (da) 2012-03-26
US20090030003A1 (en) 2009-01-29
MY147330A (en) 2012-11-30
UA94660C2 (en) 2011-05-25
SI2152712T1 (sl) 2012-03-30
MX2009011830A (es) 2009-11-13
CA2687035C (en) 2011-09-20
TN2009000471A1 (fr) 2011-03-31
KR20100007985A (ko) 2010-01-22
SV2009003411A (es) 2010-05-21
TW200902015A (en) 2009-01-16
HRP20120105T1 (hr) 2012-02-29
PA8779901A1 (es) 2008-12-18
NZ580904A (en) 2012-02-24
ATE540954T1 (de) 2012-01-15
PT2152712E (pt) 2012-02-29
IL201977A (en) 2014-07-31
CO6241157A2 (es) 2011-01-20
PL2152712T3 (pl) 2012-05-31
GT200900294A (es) 2011-08-29
KR101222330B1 (ko) 2013-01-15
ZA200907776B (en) 2011-01-26
JP2010526863A (ja) 2010-08-05
AU2008249750B2 (en) 2011-07-14
HK1142595A1 (en) 2010-12-10
WO2008139293A1 (en) 2008-11-20
CU20090184A7 (es) 2011-07-11
EA200901373A1 (ru) 2010-06-30
NI200900204A (es) 2010-03-11
CA2687035A1 (en) 2008-11-20
BRPI0811280A2 (pt) 2015-01-20
BRPI0811280B8 (pt) 2021-05-25
RS52166B (sr) 2012-08-31
ME00954B (me) 2012-06-20
CU23834B1 (es) 2012-10-15
PE20090247A1 (es) 2009-03-13
EP2152712B1 (en) 2012-01-11
JP4579346B2 (ja) 2010-11-10
GEP20125405B (en) 2012-02-27
ES2377849T3 (es) 2012-04-02
TWI362262B (en) 2012-04-21
DOP2009000258A (es) 2010-05-15

Similar Documents

Publication Publication Date Title
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2014002518A1 (es) Compuestos derivados heterociclicos nitrogenados, inhibidores de la bace-1 o de la bace-2; composicion farmaceutica que los comprende; combinacion farmaceutica; su uso en el tratamiento o prevencion de la enfermedad de alzheimer o un deterioro cognitivo leve.
PA8740901A1 (es) Compuestos organicos
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
CL2013003472A1 (es) Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras.
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2007001731A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2007003879A1 (es) Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CL2008001025A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2007001732A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.